Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion.
Autotaxin (ATX) is a prometastatic enzyme initially isolated from the conditioned medium of human melanoma cells that stimulates a myriad of biological activities, including angiogenesis and the promotion of cell growth, survival, and differentiation through the production of lysophosphatidic acid (LPA). ATX increases the aggressiveness and invasiveness of transformed cells, and ATX levels directly correlate with tumor stage and grade in several human malignancies. To study the role of ATX in the pathogenesis of malignant melanoma, we developed antibodies and small-molecule inhibitors against recombinant human protein. Immunohistochemistry of paraffin-embedded human tissue shows that ATX levels are markedly increased in human primary and metastatic melanoma relative to benign nevi. Chemical screens identified several small-molecule inhibitors with binding constants ranging from nanomolar to low micromolar. Cell migration and invasion assays with melanoma cell lines show that ATX markedly stimulates melanoma cell migration and invasion, an effect suppressed by ATX inhibitors. The migratory phenotype can be rescued by the addition of the enzymatic product of ATX, LPA, confirming that the observed inhibition is linked to suppression of LPA production by ATX. Chemical analogues of the inhibitors show structure-activity relationships important for ATX inhibition and indicate pathways for their optimization. These studies suggest that ATX is an approachable molecular target for the rational design of chemotherapeutic agents directed against malignant melanoma.
Department of Molecular Biophysics and Biochemistry, Yale University, P. O. Box 208114, New Haven, CT 06520-8114, USA.
Lauren P
LP
Saunders
Amy
A
Ouellette
Russ
R
Bandle
William Chozen
WC
Chang
Hongwen
H
Zhou
Raj N
RN
Misra
Enrique M
EM
De La Cruz
Demetrios T
DT
Braddock
D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects*; D006801:Humans; D006868:Hydrolysis / Q000187:drug effects; D007700:Kinetics; D008545:Melanoma / Q000201:enzymology / Q000473:pathology*; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors* / Q000302:isolation & purification; D009361:Neoplasm Invasiveness; D009506:Nevus / Q000201:enzymology; D043264:Phosphodiesterase I / Q000037:antagonists & inhibitors* / Q000302:isolation & purification; D010727:Phosphoric Diester Hydrolases / Q000378:metabolism; D011755:Pyrophosphatases / Q000037:antagonists & inhibitors* / Q000302:isolation & purification; D012867:Skin / Q000201:enzymology; D054852:Small Molecule Libraries / Q000032:analysis* / Q000737:chemistry / Q000494:pharmacology*; D000099189:Lysophospholipase D
D009097:Multienzyme Complexes; D043264:Phosphodiesterase I; D010727:Phosphoric Diester Hydrolases; D011755:Pyrophosphatases; D054852:Small Molecule Libraries; D000099189:Lysophospholipase D